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Abstract
Normal blood clotting is regulated by blood plasma protein factors in a blood
coagulation cascade. Deficiency in one of these proteins, Factor VIII (FVIII), causes the
disease hemophilia A, in which the patient is unable to form blood clots. Treatment of
hemophilia A involves the infusion of FVIII, and the most common complication in this
treatment is the development of antibodies against the therapeutic infusions. Two
mouse monoclonal anti-human antibodies, 3E6 and G99, were used as models of
inhibitory action against FVIII by binding to the C-terminal C2 domain. A classical
antibody, 3E6, blocks the ability of FVIII to bind von Willebrand Factor, a circulatory
partner. The classical antibody thereby reduces the stability of FVIII in plasma. A
nonclassical antibody, G99, blocks the activation of FVIII, inhibiting the role of FVIII in
the blood coagulation cascade. In order to study the inhibitory action of classical and
nonclassical antibodies, 3 complexes were prepared, C2:3E6, C2:G99, and 3E6:C2:G99.
Small angle X-ray scattering was used to study the structures of the C2 domain in
complex with the antigen binding fragment (Fab) of each antibody and in complex with
both Fabs simultaneously. Reproducible, low-resolution models of the complexes were
generated from scattering data using a software suite from the European Molecular
Biology Laboratory. The scattering data for 3E6:C2:G99 was used to generate an
elongated shape with antibodies on opposite sides of the C2 domain. Extensive crystal
trials were undertaken to prepare for future X-ray crystallography studies of the
complexes.
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Background

History of Hemophilia A

Hemophilia A is a disease caused by a deficiency in blood coagulation factor VIII (FVIII)
afflicting 1 in 5000 males [1, 2] with an inability to form effective blood clots. The
bleeding episodes caused by hemophilia A have been recorded in the Talmud [3], a
document of Jewish law written circa 200 AD. Also, the Islamic surgeon Albucasis
described a hereditary bleeding condition in Al Tasrif, a widely-used tenth century
medical encyclopedia [4]. The well-studied history of hemophilia in the European royal
families begins with Queen Victoria, a hemophilia carrier whose son died in 1861 and
ends with Victoria's last descendant in 1945 [5]. A granddaughter of Queen Victoria
famously sought the help of the Russian mystic Rasputin to heal her son’s hemophilia in
1905 [6].

The first publishing of a successful transfusion of blood for a hemophilia patient came in
1840 wherein the provider “decided not to let the boy die” [7].

Use of blood

transfusions became common by the 1950s [8]. The frequent receipt of pooled human
blood transfusions led to a disproportionate and tragic state of affairs for the
hemophilia population during the AIDS crisis in the 1980s in the United States.
Approximately 40% of that era’s hemophilia population eventually died of AIDS [9].

Almost all of the U.S. hemophilia population who received repeated infusions of
untreated blood products contracted the hepatitis C virus [10, 11]. The hazards of using
blood hastened the development of recombinant coagulation products. In 1987 Gilbert
White II administered the first dose of hamster cell-derived recombinant FVIII to a
patient who then pretended to be transformed into a hamster [9]. Recombinant FVIII
product was licensed shortly thereafter and comprises 88% of the FVIII administered
currently [9].

Tested, plasma-derived FVIII products and recombinant FVIII are both used for
treatment now, and no hemophilia patients in the U.S. or Europe have contracted HIV or
hepatitis from hemophilia therapy for over 20 years. Due to infection with hepatitis C
during the crisis, however, there remains a legacy of patients with both diseases.
Treatment of hepatitis C compounds the symptoms of hemophilia A. A patient who
decides to undergo the year-long attempt to cure hepatitis C will be subjected to
potential anemia and increased joint pain [12]. The most significant complication in
treating hemophilia A, though, is the development of antibodies against the FVIII
infusions [13].
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Blood Coagulation Cascade

FVIII serves as a critical glycoprotein in the intrinsic pathway of the blood coagulation
cascade shown in Figure 1. The cascade is responsible for the formation of a blood clot,
and it begins at the site of vascular damage. When a blood vessel is injured, platelets
form aggregates on exposed epithelial macromolecules [14]. The platelets present
negative charges on their surfaces. The negative charge need not be on platelet
surfaces, however, as blood coagulation has long been artificially initiated on glass.
When circulating plasma cofactors, numbered I - XIII encounter the negative charge,
they are serially activated and two enzymatic complexes are formed: the intrinsic
tenase complex and the extrinsic tenase complex.

Both complexes include the

anchoring platelet phospholipid surface and calcium ion [15], and both complexes
proteolytically cleave the zymogen factor X (FX) to form the active FX (FXa, a = active)
enzyme [16] which activates prothrombin into thrombin. Thrombin cleaves fibrinogen
into less soluble fibrin monomers that polymerize around the aggregated platelets [17].
Thrombin also activates FXIII to form a hard clot by cross-linking the fibrin polymers
[18].

3

Prekallikrein

Kallikrein
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XIIa
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Figure 1. Blood coagulation cascade. Plasma protein factors are represented by black
roman numerals or name (see Table 1). Activated factors are green. The intrinsic
pathway (pink) starts with contact (underlined in figure) with the negatively charged
phospholipids of activated platelets. Intrinsic and extrinsic (blue) pathways converge
upon activation of factor X (X) to factor Xa (Xa), and thrombin enhances several steps
in the coagulation cascade. Thrombin additionally facilitates conversion from soluble
fibrinogen to the cross-linked, insoluble fibrin which comprises a hard clot.
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Factor
Prekallikrein
I
II
III
IV
V
VII
VIII
IX
X
XI
XII
XIII

Name

Fletcher Factor
Fibrinogen
Prothrombin
Tissue Factor
Calcium ions
Proaccelerin; Labile Factor
Stable Factor; Proconvertin
Antihemophilic Factor A; Antihemophilic
Globulin
Christmas Factor; Antihemophilic Factor B
Stuart-Prower Factor
Plasma Thromboplastin Antecedent
Hageman Factor
Fibrin-stabilizing Factor

Pathway
Intrinsic
Both
Both
Extrinsic
Both
Both
Extrinsic
Intrinsic
Intrinsic
Both
Intrinsic
Intrinsic
Both

MW
(kDa)
69
340
72
44

Function
precursor
zymogen
cofactor
cofactor

330
50

cofactor
zymogen

285
57
59
160
76
320

cofactor
zymogen
zymogen
zymogen
zymogen
zymogen

Table 1. Table of the blood coagulation factors. Pathways, molecular weights (MW),
and functions are indicated for plasma protein factors. FVI was found to be FVa so
there is no FVI.

Many of the factors in the coagulation cascade are zymogens and they are indicated in
Table 1.

The active factors thrombin, FVIIa, FIXa, and FXa are trypsin-like serine

proteases. Their predecessors are zymogens, but unlike the digestive protein trypsin,
these 4 factors can only be activated when bound to Ca2+ [19, 20]. Their metal-binding
ability is due to the presence of 10 – 12 γ-carboxyglutamic acids within their N-terminal
domains [19]. An N-terminal domain containing several γ-carboxyglutamic acids is
called a Gla domain, and the Gla domains of thrombin, FVIIa, FIXa, and FXa are involved
in binding to membrane surfaces [19, 20]. FXIa and FXIIa are serine proteases, but they
do not contain Gla domains.
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Intrinsic Pathway

The intrinsic pathway of the coagulation cascade shown in Figure 1 is strongly enhanced
by thrombin and components of the extrinsic pathway, and it is initiated by negative
charge on the surfaces of activated platelets. The negative charge is responsible for FXII
activation to FXIIa [21, 22]. FXIIa begins a feedback loop converting prekallikrein to
kallikrein, amplifying its own production [23, 24]. FXIIa additionally cleaves FXI to FXIa
[25] which in turn cleaves FIX into FIXa, moreso in the presence of extrinsic factor FVIIa
docked onto tissue factor (TF) [26, 27]. FVIIIa, activated from FVIII by thrombin or FXa
[28], is a member of the intrinsic tenase complex. FVIIIa recruits FIX to the platelet
surface and amplifies its activation to FIXa [18]. FIX activation is further enhanced by
FVa, a homologue of FVIII and the final component of the intrinsic pathway. Like FVIII,
FV is cleaved by thrombin [29]. The intrinsic tenase complex (shown in Figure 2)
proteolytically cleaves FX to FXa, which in turn generates thrombin.

Extrinsic Pathway

FXIIa produced in the intrinsic pathway catalyzes the cleavage of FVII to FVIIa, the first
step of the extrinsic pathway shown in Figure 1.

FVIIa binds to integral membrane

protein tissue factor (TF) from exposed epithelial cells [30] forming the extrinsic tenase
6

complex. The extrinsic pathway is so named because the TF component is not a plasma
protein whereas all components of the intrinsic pathway are plasma proteins.

Although the extrinsic pathway contains enough factors to generate a blood clot in the
absence of an intrinsic tenase complex, blood clotting is deficient without intrinsic FVIII.
The requirement of FVIII for clotting is partly due to the regulation of the extrinsic
pathway. The plasma protein tissue factor pathway inhibitor (TFPI) inhibits Xa and the
activity of the extrinsic tenase complex [31]. TFPI down-regulates the extrinsic pathway
so hemostasis requires the longer lasting intrinsic pathway and its intrinsic tenase
complex.

Intrinsic Tenase Complex

FVIII is cleaved by serine proteases FXa and thrombin to active FVIII (FVIIIa) [28, 32].
FVIIIa binds to platelet surfaces with a dissociation constant KD ~ 0.8 nM [33]. In the
presence of calcium ions, FVIIIa recruits active FIX (FIXa) to the platelet surface [18, 34,
35] where FVIIIa aides the conformational change of FIX [36] and completes the
formation of the intrinsic tenase complex (Figure 2). The FIXa is then 100,000 times
more active at cleaving FX than when FIXa is free in solution [37].

7

Figure 2. Intrinsic tenase. Active factor VIII (FVIIIa) and active factor IX (FIXa) are both
bound to the negative charge on the surface of a platelet in the presence of calcium
ion. This complex is the intrinsic tenase, responsible for cleaving factor X (FX) to its
activated form FXa.

Factor VIII

The 186 kb gene of FVIII is situated on the long arm of the X chromosome [38]. FVIII is
synthesized in human liver, spleen, lung, and lymph node cells [39] as a single chain of
2351 amino acids including a 19 amino acid signal peptide [40, 41]. When the signal
peptide is cleaved, mature FVIII is a 2332 amino acid peptide organized into the
following domains (capitalized) and acidic regions (italicized): A1 (residues 1-336), a1
(337-372), A2 (373-710), a2 (711-740), B (741-1648), a3 (1649-1689), A3 (1690-2019),
C1 (2020-2172), C2 (2173-2332). The domain structure is illustrated in Figure 3.
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Figure 3. Factor VIII (FVIII) with domains in color. Left: Crystal structure of the Bdomain deleted Factor VIII with domains A1 (blue), A2 (green), A3 (yellow), C1
(orange), and C2 (red) (PDB accession number 2R7E) [42]. Right: Sequence of FVIII
domains in protein expression, circulation, and active form. FVIII is expressed as a
single chain. The B domain is then cleaved, and the protein circulates as a
heterodimer in complex with von Willebrand Factor (vWF). When activated, vWF is
released, the B domain and acidic region a3 are removed entirely, and the A2 domain
is cleaved from the a1 acidic region so FVIII is a heterotrimer.

The crystal structure of the fully active, B-domain-deleted recombinant FVIII was
published in 2008 and is shown in Figure 3 [42]. The heterodimer of heavy chain (A1A2) and light chain (A3-C1-C2) was shown to associate in a stable conformation with the
exception of the C2 domain which appears to be associated by a minimal buried surface
area. Within the light chain the C2 domain shares a 400 Å 2 hydrophobic interface with
the C1 domain and a 200 Å2 hydrophobic interface with the A1 domain as compared to
the 1200 Å2 interface between C1 and A3 domains [42]. The A1, A2, and A3 domains
have a root mean square deviation (rmsd) of 1.40 Å, indicating high structural homology
with each other [43]. The A domains of FVIII also have homology with ceruloplasmin
9

(rmsd = 1.7 Å) and with the A1 and A3 domains of FV (rmsd = 2.2 Å) [42]. The FVIII C1
and C2 domains have high structural homology with each another (rmsd = 1.09 Å) [43].
Disulfide bridges are present across 153-179 and 248-329 cysteine residues in the A1
domain, 528-554 and 630-711 in the A2 domain, 1832-1858 and 1899-1903 in the A3
domain, 2021-2169 in the C1 domain, and 2174-2326 in the C2 domain [44, 45].
Residues 310 (A1 domain), 692 (A2 domain), and 2000 (A3 domain) have been identified
as free cysteines [44]. The acidic regions, sometimes called activation peptides, contain
high percentages of glutamic and aspartic acids. They also contain sites capable of
tyrosine sulfation at position 346 of the a1 region, 718, 719, and 723 of the a2 region,
and 1664 and 1680 of the a3 region [46, 47]. N-linked glycosylation has been confirmed
in 20 of the 25 potential glycosylation sites of FVIII [46]; they are residues 42, 239, 757,
784, 828, 900, 963, 1001, 1005, 1055, 1066, 1185, 1255, 1259, 1282, 1300, 1412, 1442,
1810, and 2118. Nonglycosylated or partially glycosylated residues are 582, 943, 1384,
and 1685. The glycosylation of 1512 residue has not been determined.

FVIII has been shown to bind metal ions, and 4 such ions were present in the A domains
of the 2008 crystal structure [42]. One site was in the A1 domain, where a calcium ion
was coordinated by E110, D116, D125, and D126. Another calcium-ion-binding site was
in the A2 domain coordinated by D538 and D542. The other 2 metals were copper ions
coordinated to H1954, H2005, and C2000 in the A3 domain and H267, H315, and C310
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of the A1 domain.

The copper binding is in agreement with the homology to the

copper-binding protein ceruloplasmin.

Factor VIII and von Willebrand Factor

Inactive FVIII circulates in blood plasma as a heterodimer bound to the multimeric
plasma glycoprotein von Willebrand Factor (vWF, KD = 0.52 nM) [48]. Rapid clearance
from circulation is the fate of FVIII unbound to vWF [49]. The acidic region a3 and the
carboxyl terminus of the C2 domain, both in the light chain of FVIII, are responsible for
binding to vWF [50, 51]. The R1689-S1690 residues and the sulfated tyrosine residue
1680 of the a3 domain are required for high-affinity binding of FVIII to vWF [52, 53].
Residues within the 2303-2332 region of the C2 domain are also critical for vWF binding
affinity [51, 54], and specific vWF binding sites have been localized to M2199-F2200 and
L2251-L2252 hydrophobic loops [45, 55] as well as W2313-H2315 and Q2222-K2227 [56,
57]. The C1 domain, however, may also take part in vWF binding because its presence
enhances the binding of vWF [58].

The association of the heavy and light chains of FVIII to one another is more stable when
FVIII is coordinated to vWF [59].

vWF loses affinity for FVIII in the presence of

subendothelial cells in human arteries [60]. That is, at the site of vascular damage, vWF
is more likely to release FVIII, allowing for FVIII to become activated.
11

Factor VIII Activation and Inactivation

FVIIIa is considered active when it is a heterotrimer bound to a negatively charged
platelet surface in the presence of calcium ion. FVIII must be proteolytically cleaved,
released from vWF, and associated with FIXa on the platelet surface in order to be part
of the intrinsic tenase complex and to be active. The C2 residues responsible for binding
to vWF are also the expected binding locale for platelets [56].

FVIII can be activated to FVIIIa with cleavage by thrombin or FXa.

Thrombin

proteolytically cleaves FVIII at R372, R740, and R1689 [32], and porcine FVIII is activated
70-fold by thrombin in the presence of 5 mM CaCl2 [61, 62]. Like thrombin, FXa cleaves
FVIII at R372, R1689 [32]. Unlike thrombin, FXa also cleaves at R336 and R1721 [32].

The light chain of FVIIIa (A3-C1-C2) is primarily responsible for membrane binding [42,
63]. Just as with binding to vWF, the binding to membranes is enhanced when C2 is
associated with C1 [64]. The authors who published the 2008 crystal structure of FVIII
proposed that the binding was attributable solely to the C1 and C2 domains [42]. FVIII
binds specifically to membranes containing phosphatidyl-L-serine [65-67].

The

hydrophobic spikes in the C2 domain are expected to be submerged in the platelet
membrane as shown in Figure 4. Residues K2227, K2249, R2215, and R2220 are basic
residues which could interact favorably with the negatively charged phosphotidyl-L12

serine head groups [42, 45]. Hydrophobic spikes comprised of residues M2199-F2200,
L2251-L2252, and V2223 could favorably interact with the hydrophobic region of the
membranes [42, 45]. In fact, mutations of the hydrophobic spikes M2199-F2200 and
L2251-L2252 reduced binding to membranes 20- and 30-fold, respectively [55]. The
hydrophobic W2313-H2315 loop was additionally shown to be involved in membrane
binding [56]. The hydrophobic spikes in Figure 4 attributed to membrane binding have
some flexibility which may account for the overlap of the M2199-F2200 loop into the
hydrophilic region of Figure 4 [56].

R2215
K2227

Hydrophilic

R2220

Hydrophobic
W2313-H2315 V2223

K2249

M2199-F2200
L2251-L2252

Figure 4. Potential binding of FVIII to phospholipid surface. Basic residues proposed
to be involved in contact with negative charge on the platelet surface are shown in
blue.
Hydrophobic residues purportedly buried in the hydrophobic platelet
membrane are shown in green.
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Inactivation of FVIIIa is accomplished when it is degraded by proteolytic cleavage, the
heterotrimer disassociates, and is cleared from the site of vascular damage and
circulation. Activated protein C (APC) cleaves R562-G563, R336-M337 and R740-S741
[68], but FXa and FIXa also cleave FVIIIa [32]. It is unknown whether the proteolytic
cleavages or the dissociation of the heterotrimer are more important for inactivation,
and in which order they take place [69].

Inhibitors to FVIII

Hemophilia A is most commonly treated with repeated therapeutic infusions of
recombinant or plasma-derived FVIII. The development of inhibitors against FVIII occurs
in approximately 30% of hemophilia A patients, and as such is the most menacing
obstacle to successful treatment [70-72].

Antibodies are comprised of 2 identical heavy chains and 2 identical light chains. An
antibody that has been cleaved by a protease yields 3 fragments: 2 identical antigen
binding fragments (Fabs) and a constant fragment (Fc) as shown in Figure 5. The Fab
contains the complementarity determining region (CDR) of an antibody, which is the
region of the antibody in contact with the epitope on the antigen. The CDR of a Fab is
highly specific for binding to the epitope. The Fabs can be separated from the Fc by
digestion with the enzyme papain, and the papain cleavage sites are shown in Figure 5.
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Figure 5. Antibody structure. (A) A whole antibody contains 2 heavy chains (pink),
and 2 light chains (green). Papain cleavage sites are indicated with green arrows.
CDRs are circled. Fabs and Fc are indicated with brackets. Disulfide bonds are shown
as black blocks. (B) A cleaved antibody has 3 unconnected parts. The 2 identical Fabs
and 1 Fc are indicated with brackets, and each has a heavy chain and a light chain
connected by disulfide bonds.

In order to study the immune response to FVIII infusions, a human antibody against FVIII
was isolated by Belgian scientists from a patient with hemophilia A in 1998. The
antibody, BO2C11, is a monoclonal IgG4к, and it was shown to inhibit wild-type FVIII
procoagulant activity and the binding of FVIII to either vWF or phosphatidylserinecontaining membranes [73]. A crystal structure of BO2C11 Fab bound to the C2 domain
of FVIII was published in 2001, and the FVIII residues in contact with the inhibitor were
S2250, L2251, L2252, T2253, F2196, T2197, N2198, M2199, F2200, R2220, R2215,
Q2222, V2223, H2315, Q2316 (Figure 6) [74]. Each of these residues is within 10.6 Å of
residues proposed to be involved in membrane binding (see Figure 4).
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Figure 6. Ribbon diagram of C2 domain bound to inhibitor BO2C11. (A) The whole
complex of C2 domain (red) bound to BO2C11 Fab light chain (blue) and heavy chain
(green) is shown with a box around the enlarged section in (B) (PDB accession number
1IQD). (B) An enlarged image of the interface between C2 and BO2C11 F ab is shown.
C2 residues with side chains in contact with the Fab are colored gray and indicated with
arrows. Side chains are not shown. (PDB accession code 1IQD) [74].

Inhibitory antibodies against FVIII vary widely and defy tidy classification, but some
categories do persist in the literature. Antibodies against FVIII have been called type I or
type II based upon their action and kinetics of inhibition of phohspholipid and vWF
binding and in vitro blood coagulation [75].

However, some antibodies have

intermediate kinetics of inhibition [74, 76], and the classification of types I and II is not
clinically useful. Another distinction between antibodies against FVIII is whether they
are classical or nonclassical. Classical antibodies block the ability of C2 to bind to vWF or
to platelet membranes. Nonclassical antibodies block the activation of FVIII by thrombin
and FXa [77].
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Most antibodies against FVIII bind to the A2 or C2 domains [78], and inhibitors against
these domains can inhibit FVIII procoagulant activity [79, 80] as well as binding to vWF
and phospholipids. In order to study the diversity of inhibitory antibodies, a panel of
hundreds of monoclonal mouse antibodies against the human C2 domain was
developed by the Lollar lab at Emory University in Atlanta, Georgia [76].

These

monoclonal mouse anti-human antibodies were classified based upon overlapping
epitopes into groups A, AB, B, BC, and C. Two of the antibodies, G99 and 3E6, are used
in the present study [76]. 3E6 is a group A, classical IgG2aκ that inhibits in vitro binding
of C2 to vWF (IC50 = 0.6 μg/mL) and to phospholipids (IC50 = 0.4 μg/mL) [76]. G99 is a
group BC, nonclassical IgG2aκ that allows binding to vWF and phospholipids in vitro, but
inhibits activation by thrombin or Xa [76]. A metric called the Bethesda assay is
commonly used to quantify inhibitors of procoagulant activity, and a Bethesda unit
(BU)/mg is the dilution of inhibitor that inhibits 50% of FVIII procoagulant activity in
normal plasma [76, 81]. Human IgG BO2C11 has an inhibitor titer of 20,000 BU/mg so it
is a powerful inhibitor of blood coagulation [76]. G99 has an inhibitor titer of 15,000
BU/mg [76]. 3E6 has an inhibitor titer of 41 BU/mg so it is a weak inhibitor, but the high
concentration of IgG in plasma compared to the low concentration of plasma cofactors
allows even weak inhibitors to halt blood clotting.

3E6 and G99 are able to noncompetitively bind C2 so their epitopes are not expected to
overlap, and they are able to bind simultaneously [76]. 3E6 competes for binding with
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BO2C11 [76] so there is expected overlap between the unknown epitope of 3E6 and the
solved epitope of BO2C11 [74]. G99 does not compete with BO2C11 for binding, but
binding to C2 was inhibited by the mutation K2227E so the 2227 residue is expected to
be in or near the G99 epitope [76].

The original objective of this study was to characterize the C2 domain bound to 3E6 and
G99 in binary complexes and C2 bound to both antibodies using X-ray crystallography.
X-ray crystallography data are more clearly interpreted when fewer atoms are present
because each atom complicates the diffraction pattern. To minimize the atoms present
in the complex, the Fabs of the antibodies were isolated and the C2 domain was used in
lieu of the entire FVIII molecule. Crystal growth was not achieved, however, so another
structural determination method, small angle X-ray scattering (SAXS), was used. Crystal
trials are still underway, but all results in this thesis are based on SAXS data.

Structural Determination Using X-Rays

SAXS and X-ray crystallography both utilize X-ray diffraction to give information about
the structure of proteins. X-rays are suitable for revealing electron density because a
quantum of X-ray radiation is close to the ~ 8000 eV energy of an electron in its orbital
[82]. When an X-ray beam encounters the oscillating dipole in an atom it is reflected in
the shape of a sphere. As the reflected X-rays constructively and destructively interfere,
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a pattern of diffraction emerges that provides information about the electron density
within the sample scattering the X-rays.

X-Ray Crystallography

A protein crystal is a highly-ordered symmetric solid with a repeating pattern grown in a
liquid matrix. A crystal contains identical unit cells stacked in 3 dimensions. Each corner
of the unit cell is localized on a crystal lattice. Further, each crystal lattice in a unit cell
can be superimposed on every other crystal lattice by translational motion. A crystal
lattice is comprised of 1 or more asymmetric unit. The asymmetric units in a crystal
lattice are related by symmetry. A unit cell, crystal lattice, and asymmetric unit are
illustrated in Figure 7.

Figure 7. Unit cell, crystal lattice, and asymmetric unit of a crystal. A crystal is made
of unit cells repeated in all directions. Each corner of the unit cell is on a crystal
lattice. Each crystal lattice contains at least 1 asymmetric unit. An asymmetric unit
has no internal symmetry [82].
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The hanging drop method is a technique used to grow protein crystals for X-ray
crystallography. In this technique a precipitant is added to a drop of the solution
containing the target molecule. By creating a concentration gradient in a closed system,
the crystallographer uses vapor diffusion to remove water from the drop, bringing the
target molecules to the point of supersaturation and hopefully nucleating crystal
growth. Nucleation can also be affected by the addition of small, nucleated crystals into
an equilibrated drop. Varied temperature and precipitant conditions are screened in
attempts to grow crystals, and these attempts are called sparse matrix crystal trials.
Once a clear crystal with well-defined sides is identified, the crystal is frozen in liquid
nitrogen then irradiated with X-rays, and diffraction data are collected as a function of
crystal rotation.

An X-ray crystallography instrument is comprised of an X-ray source, a stage for the
crystal, and a detector adjacent to the X-ray beam.
diffraction pattern of spots called reflections.

Crystallography results in a

The intensity and position of the

reflections are interpreted to find the atomic resolution electron density of the protein.
Since the crystals are biological compounds grown in solution, they have some water
content, and the placement of the water molecules must therefore be solved with the
structure.
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Small Angle X-Ray Scattering (SAXS)

SAXS is a complementary technique to X-ray crystallography because, unlike in
crystallography, SAXS data is collected from dispersed non-crystalline samples in
solution. SAXS is a characterization technique that yields 10 - 20 Å resolution structural
data for macromolecules in solution [83]. As with X-ray crystallography, SAXS data
include the intensity and position of X-rays reflected off the sample. SAXS data are
collected at a synchrotron by beamline scientists. The samples are irradiated for 3
different exposure times and an identical buffer must be provided for calibration.

The initial result of SAXS is generation of a plot of I(q), the intensity of the waves
scattered by the sample. q is the momentum transfer, and q = (4πsinθ)/λ where 2θ is
the angle between the transmitted and scattered beam and λ is the wavelength of
radiation [84]. From the raw data, a Guinier Plot can be made. A Guinier plot is a plot of
natural log of I(q) versus q2, and its shape can indicate whether the sample in solution is
monodisperse or aggregated [85]. The intensity of scattered radiation at 0⁰ is called I(0),
and it is extrapolated from the Guinier plot. I(0) provides the radius of gyration (RG), the
mass distribution of the macromolecule around the center of gravity, from the
relationship I(q) = I(0) exp {-q2RG2/3} [84]. The distribution of paired electron distances
is called P(r), and it can be plotted from SAXS data. The shape of P(r) can show whether
the target molecule is globular or has distinct domains or subunits. It cannot, however,
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distinguish between domains and subunits. The P(r) yields parameters called real space
RG and real space I(0) based on all data points. The Guinier plot, in contrast, has data
truncated for finding RG. Another plot called the Kratky plot is I(q)*q2 versus q, and it
can identify whether the molecule is folded or unfolded [85]. This attribute of SAXS
makes it useful for samples which change conformation during irradiation, but the
complexes in this study were not examined for conformational changes.

Most

importantly, SAXS yields a molecular envelope called an ab initio (from the beginning)
structure. While X-ray crystallography examines a highly ordered and static structure,
SAXS probes a disordered sample with each molecule oriented differently. The ab inito
shape is therefore the shape of the molecule that would generate the distinct data set.
This ab initio shape defines the structure most likely to generate the experimental SAXS
scattering curves. The low resolution structure can be used to verify complementary
structural data found with X-ray crystallography [86]. In turn, molecular replacement
with known structures can enhance the information provided by SAXS. The SAXS plots
and parameters described above are tabulated (Table A-1 and Table A-2), and a
procedure for processing SAXS data is outlined in detail in Appendix 1.

Specific Aims

The first specific aim of this study was to prepare pure C2 domain, 3E6 Fab, and G99 Fab.
The C2 domain was expressed in bacteria then purified. Whole antibodies were purified
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from crude antibody mixtures, cleaved with papain digestion, then the Fabs were
isolated. The second aim was to form and purify the binary complexes C2:3E6 and
C2:G99 and the ternary complex 3E6:C2:G99 where a complex is the C2 domain and 1
Fab of each antibody. Complexes were formed by room temperature incubation and
purified with size exclusion chromatography. The third aim was to characterize the
complexes using SAXS, and the fourth aim was to conduct crystal trials to prepare for Xray crystallography.
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Materials and Methods
Buffers
C2 lysis buffer: 300 mM NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole, 0.01% (v/v)
Triton X 100, 1 mM phenylmethanesulfonyl fluoride (PMSF, added just before use), 2.5%
(v/v) glycerol

C2 wash 1 buffer: 300 mM NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole, 2.5% (v/v)
glycerol

C2 wash 2 buffer: 150 mM NaCl, 20 mM Tris-HCl (pH 7.0), 10 mM imidazole, 2.5% (v/v)
glycerol

C2 elution buffer: 150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 150 mM imidazole, 2.5% (v/v)
glycerol

C2 thrombin cleavage buffer: 50 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5 mM CaCl2, 2.5%
(v/v) glycerol

C2 low salt buffer for TALON: 50 mM NaCl, 20 mM Tris-HCl (pH 8.0), 10 mM imidazole,
2.5% (v/v) glycerol
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C2 standard low salt buffer: 50 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5% (v/v) glycerol

C2 high salt buffer: 500 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2.5% (v/v) glycerol

C2 storage buffer: 50 mM NaCl, 25 mM Tris-HCl (pH 8.0)

Antibody sample buffer: 20 mM sodium phosphate, 10 mM ethylenediaminetetraacetic
acid (EDTA, pH 7.0)

Antibody digestion buffer: 20 mM cysteine hydrochloride, 20 mM sodium phosphate, 10
mM EDTA (pH 7.0)

Electrophoresis gel reducing load dye: 2% (w/v) SDS, 80 mM Tris-HCl (pH 6.8), 10% (v/v)
glycerol, 0.002% (w/v) bromophenol blue, 5% (v/v) β-mercaptoethanol (BME)

Electrophoresis gel non-reducing load dye: 2% (w/v) SDS, 80 mM Tris-HCl (pH 6.8), 10%
(v/v) glycerol, 0.002% (w/v) bromophenol blue

Electrophoresis gel destain buffer: 40% (v/v) methanol, 10% (v/v) glacial acetic acid,
50% nanopure water
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Protein Expression

E. coli BL21 cells were transformed with pET15b vector, a plasmid containing ampicillin
resistance and a multiple cloning site for (His)6-tagged FVIII C2 domain and grown on
agar gel plates containing 50 μg/mL ampicillin [87]. Seed cultures were grown overnight
from single colonies or seed stocks in 10 mL Luria-Bertani media (LB, 10% (w/v)
BactoTryptone, 5% (w/v) yeast extract, 10% (w/v) NaCl) containing 50 μg/mL ampicillin.
Seed stocks were comprised of 50% (v/v) seed culture, 25% (v/v) glycerol, 25% (v/v)
nanopure water and were stored at -20 °C. 1 L LB cultures containing 50 μg/mL
ampicillin were inoculated with seed cultures and shaken at 37 °C until optical density at
600 nm was 0.6-0.8 (4 hours). The cultures were then induced with 0.5 M isopropylthioβ-D-galactoside (IPTG) and were shaken at 15 °C overnight. The cells were harvested by
centrifugation at 4 °C and 8000 rpm for 10 minutes (FIBERLite F10-6x500y carbon fiber
rotor, Piramoon). The cell pellet from a 1 L growth was resuspended in 35 mL lysis
buffer with 0.5 - 0.8 mg/mL lysozyme at 4°C for about 1 hour. The lysis solution from 3 6 L growth was then pooled and sonicated on ice in 3-5 60 second sessions using a 1/2”
titanium horn attached to Branson Sonifier 450 (50% duty cycle). The lysate was spun
down at 4°C for 30 minutes at 16,000 rpm (FIBERLite F21-8x50y carbon fiber rotor,
Piramoon), then filtered through 0.8 μm cellulose sterile syringe filters.
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Protein Purification

TALONTM metal affinity resin (ClonTech) was equilibrated with C2 lysis buffer in a gravity
flow column. Equilibrated resin was incubated at 4°C for 1 hour with filtered lysate at a
ratio of 1 mL of settled resin to lysate from 1 L of culture. The resin and lysate mixture
was then returned to a gravity flow column and rinsed with lysis buffer until the color of
200 μL Coomassie Protein Assay Reagent (Thermo Scientific) was unchanged by the
addition of 5 μL of eluent. The resin was then rinsed with C2 wash 1 buffer followed by
C2 wash 2 buffer until eluent showed no protein in the same Coomassie protein assay.
The resin was then rinsed with C2 elution buffer containing 150 mM imidazole, and
(His)6-tagged C2 was collected on ice (yield 4.5 mg/ 1 L of culture). The eluent was
exchanged into C2 thrombin cleavage buffer and concentrated to 1-4 mg/mL using a
100,000 Dalton molecular weight cut off concentrator (Millipore).

1 Unit of thrombin in 10 μL thrombin cleavage buffer was added per each 100 μg of
(His)6-tagged C2 in order to cleave the (His)6-tag. The cleavage reaction was incubated
overnight at room temperature. TALON resin in the ratio of 0.5 mL of settled resin for 6
L culture (27 mg protein) was equilibrated in a gravity flow column with C2 low salt
buffer for TALON. Benzamidine SepharoseTM 6B resin (GE Healthcare) in the ratio of
0.25 mL of settled resin for 6 L growth was equilibrated in a gravity flow column with C2
standard low salt buffer. The cleavage product was then run over the Benzamidine
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Sepharose resin to remove thrombin. The eluent was applied to the TALON resin to
remove cleaved (His)6-tags and uncleaved (His)6-tagged C2. The TALON eluent was then
applied to a 5 mL column of Macro PrepTM Strong Cation Exchange Support (Bio-Rad
Laboratories) equilibrated with C2 standard low salt buffer and connected to an
ÄKTAprime plusTM compact liquid chromatography system (GE Healthcare). The cleaved
protein was eluted with a linear gradient to C2 high salt buffer. The eluted, cleaved C2
was exchanged into C2 storage buffer and concentrated to 6-8 mg/mL. A HiLoadTM
16/60 Superdex 75 prep grade size exclusion column (120 mL column volume, GE
Healthcare) was attached to the ÄKTAprime plus and equilibrated with C2 storage
buffer. The C2 was injected onto the size exclusion column (SEC) via a 2- or 5-mL loop,
and the purified C2 eluent was collected.

Antigen Binding Fragment Purification

Monoclonal hybridoma cell lines derived from mice were the generous gift of the Lollar
Lab at Emory University in Atlanta, Georgia. Antibodies were produced by the Antibody
Production Facility of the Fred Hutchinson Cancer Research Center in Seattle,
Washington.

The 2 cell lines each yielded a single monoclonal antibody: 3E6

immunoglobulin G (IgG) or G99 IgG. The antibodies were purified separately with the
following procedure. Crude antibodies were incubated at room temperature for 15
minutes on a NAbTM Protein A Plus spin column (Thermo Scientific) equilibrated in
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phosphate buffered saline (PBS). The flow-through and two subsequent washes with 5
mL PBS were discarded. The pure immunoglobulin Gs (IgGs) were eluted with 3 - 5 mL
washes of 0.1 M glycine (pH 2-3) into 0.5 mL of 1 M Tris (pH 8-9) and concentrated to 20
mg/mL in antibody sample buffer. Immobilized papain on a cross-linked, 6% beaded
agarose support (Thermo Scientific) was equilibrated in digestion buffer. The pure IgG
was then diluted with an equal volume of antibody digestion buffer and incubated
overnight in a 37 °C shaker with immobilized papain in the ratio of 0.25 mL of settled
resin to 10 mL of antibody in digestion buffer. The digested antibodies were applied to
the same Protein A column equilibrated in PBS, and the flow-through contained the
desired antigen binding fragments (Fabs). The Fabs were then buffer exchanged into C2
standard low salt buffer and applied to the SEC for a final purification before the
complex was formed.

Electrophoresis

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used as
previously described [88-90] to confirm the purity and identity of Fabs, human C2, and
complexes. Samples were applied to the wells following staining by reducing or nonreducing electrophoresis gel load dye and denaturing by heating at 90 °C for 3 min.
Figure legends indicate whether reducing or non-reducing dye was used and the
percentage (%w/v) of acrylamide used to make gels. An electrical field ranging from
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100V to 145V was applied. Gels were stained using Coomassie brilliant blue dye and
destained using gel destain buffer. Bands were interpreted based molecular weight
reference standards.

Either EZ-RunTM Pre-Stained Rec Protein Ladder (Fisher

Bioreagents) or SpectraTM Multicolor Broad Range Protein Ladder (Thermo Scientific)
was used as indicated in figure captions.

Binding Assays

Nickel-nitrilotriacetic acid resin (Thermo Scientific) or TALON resin was equilibrated in
C2 wash 2 buffer and 100 μL of settled resin were applied to each of 3 microcentrifuge
tubes. 100μL of 60 μM human (His)6-tagged C2 was applied to the first column; 100 μL
of 50 μM G99 Fab were applied to the second column. Following 15 minutes of room
temperature incubation of 50 μL of each 60 μM (His)6-tagged C2 and 50μM G99 Fab, the
combined 100 μL were applied to the third column. Each column was washed with 200
μL C2 wash 2 buffer, followed by centrifugation at 2K rpm. The supernatant was
retained for SDS-PAGE. Following 4 rinses with 300 μL C2 wash 2 buffer, 300 μL of C2
elution buffer was applied to each of the columns. The columns were incubated at
room temperature for 15 minutes, spun at 2K rpm and the supernatant was collected
for SDS-PAGE. An identical protocol was used to assess binding of C2 to 3E6 Fab.
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Complex Purification

Pure 3E6 Fab (10 - 30 mg/mL) was incubated at room temperature for 30 minutes with a
1.5X molar excess of pure C2 (2 - 10 mg/mL) before being applied to the SEC
equilibrated in C2 storage buffer.

The eluent of the C2:3E6 binary complex was

collected and concentrated to 6 - 8 mg/mL as estimated by Bradford assay for
crystallization trials.
identically.

The C2:G99 binary complex was generated separately and

A ternary 3E6:C2:G99 complex was similarly formed using equimolar

concentrations of 3E6 and G99 Fabs and a 1.5X molar excess of C2.

Mass Spectrometry

A sample of pure 2 mg/mL 3E6 Fab and a sample of pure 2 mg/mL G99 Fab were each
buffer exchanged into ammonium acetate. Then the G99 and 3E6 Fabs were diluted to
10 μM and 13 μM, respectively with 50% water, 50% acetonitrile containing 0.1% formic
acid. Mass spectra were collected with an Atmospheric Pressure Ionization 2000 Triple
Quadrupole mass spectrometer (Applied Biosystems) using electrospray ionization.
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Crystal Trials

Pure 3E6:C2 and G99:C2 binary complexes and 3E6:C2:G99 ternary complexes were
concentrated to 6 - 10 mg/mL for crystal trials. The hanging drop method was used as
follows. A thin line of petroleum jelly was applied to the rim of each well in a 24-well
plate (Hampton Research) with a syringe. A 400 μL reservoir of mother liquor was
applied to a well in a 24 well plate. A 1.5 μL drop of reservoir was added to a 1.5 μL
drop of complex on the surface of a glass slide. The slide was then inverted onto the
well so the drop and mother liquor were in the same sealed system. Trials were
performed using as mother liquor each condition in IndexTM, Crystal Screen ITM, Crystal
Screen IITM, PEG/Ion ScreenTM, PEG/Ion II ScreenTM Formulations (Hampton Research),
Precipitant Synergy ITM, Cryo I, and Cryo II Formulations (Emerald Biosystems). Each of
these formulations contained 48 - 64 conditions of varied ions, buffer, precipitant,
and/or polymer. The drops were examined with optical microscopy for potential crystal
growth after 1 day, several days, 1 week, and several weeks. At least 2 concentrations
of each complex were screened against all of the above matrix conditions. Additional
trials were performed for 3E6:C2, G99:C2, and 3E6:C2:G99 complex at the Fred
Hutchinson Cancer Research Center using a Crystallography Mosquito Robot (TTP
Labtech). The sitting drop method was used wherein reservoir was applied by the robot
to wells in a 96-well plate, and drops were made by the robot onto a raised stage inside
the well. The reservoir was 100 μL, and each drop contained 100 nL of reservoir and
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100 nL of complex. The top of the plate was then sealed by hand to create a closed
system. Plates were prepared using each condition in Index TM, Crystal Screen ITM,
Crystal Screen IITM, NatrixTM Formulations (Hampton Research), Precipitant Synergy ITM,
Precipitant Synergy IITM, Ozma PEG 1000/4000TM, Wizard ITM, Wizard IITM, Wizard IIITM
Formulations (Emerald Biosystems), JCSG+TM, MPD SuiteTM, Nextal PEGlTM, Nextal
PEGIITM, and CationsTM Formulations (Qiagen). Drops were examined 1 or 2 days and 1
week after plates were prepared. For every drop showing crystal nucleation, 1 or 2
screens of that condition were prepared which each contained 24 conditions with
systematically varied precipitant concentration and pH. Hanging drop plates were then
prepared with the screens and examined as above.

Small Angle X-ray Scattering

Serial dilutions of each of the following samples were produced at the stock
concentration in parentheses, 2/3 that stock concentration, and 1/3 that stock
concentration: human C2 (5.4 mg/mL), 3E6 Fab (4.5 mg/mL), G99 Fab (4.8 mg/mL),
C2:3E6 binary complex (4.8 mg/mL), C2:G99 binary complex (5.5 mg/mL), 3E6:C2:G99
ternary complex (5.4 mg/mL). An identical buffer for each of the six samples was also
produced by buffer exchange. 200 μL of each concentration and buffer were applied to
a PCR-96-FS-C Microplate (Axygen Scientific), sealed with a silicone sealing mat, and
mailed to the SIBYLS Beamline at the Advanced Light Source at Lawrence Berkeley Lab in
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Berkeley, California. Attempts were made to maintain a 4 °C temperature during
transportation, but temperature could not be confirmed. Beamline scientists collected
small angle X-ray scattering results at room temperature at 0.5, 1, and 6 second
exposures to the photon beam. PRIMUS software [91] was used to subtract electron
density due to bulk solvent, and to find parameters. Further parameters and structures
were processed with the software programs GNOM [92], DAMMIN [93], CRYSOL [94],
SASREF [95], and SUPCOMB [96].
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Results and Discussion
Preparation of Pure C2

Purified C2 was prepared by bacterial expression and 5 column chromatography steps.
(His)6-tagged C2 was expressed in E. coli, and an initial purification was performed by
affinity chromatography. The (His)6-tag of C2 bound to TALON resin, then eluted when
imidazole concentration was raised to 150 mM, resulting in a C2 domain fraction that
was 70 – 90% pure. The (His)6-tag was then cleaved by thrombin in an overnight
enzyme digestion at room temperature, and the bulk of the thrombin was removed by
subjecting the purified C2 sample to a Benzamidine Sepharose gravity flow column. The
sample was then flowed through a TALON gravity flow column to remove (His)6-tags and
uncleaved C2.

Next, the C2 domain was further purified by ion exchange

chromatography. The C2 bound to the S column in the presence of 50 mM NaCl and
subsequently eluted in a NaCl concentration gradient raised to 500 mM. The eluted C2
was then concentrated to 6 - 8 mg/mL and the glycerol was removed by buffer
exchange. The salt concentration was also reduced in the buffer exchange. A final
purification of cleaved C2 was performed using size exclusion with a Superdex 70
column to ensure the purity of the sample. SDS-PAGE of the C2 purification is shown in
Figure 8.
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Figure 8. 15% SDS-PAGE gels of C2 purification. (A) Lanes: 1, TALON-purified cleavage
control of C2; 2, C2 thrombin cleavage product; 3, C2 cleavage product after ion
exchange. (B) Lanes: 1, C2 thrombin cleavage product; 2, Pure, cleaved C2 after SEC
purification.

Both cleaved and (His)6-tagged C2 showed their expected bands at 18452 Daltons and
20334 Daltons, respectively.

Cleaved C2 of high purity was achieved following

purification by ion-exchange chromatography and SEC.

Preparation of Pure Fabs

Batches of whole 3E6 and G99 immunoglobulin G (IgG) were produced by an offsite
antibody production facility from cell lines provided by the Lollar lab at Emory University
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(Atlanta, GA). These crude antibodies were purified using separate columns containing
immobilized Protein A. Protein A is a cell-surface protein used to recruit antibodies, and
it binds to the constant fragment (Fc) of an antibody. Pure, whole IgG eluted from the
protein A column in the presence of 0.1 M glycine at pH 2-3.

This eluent was

immediately added to a neutralizing buffer to restore physiological pH. Once whole IgG
was purified, cleavage of the antigen binding fragments (Fabs) from the Fc was achieved
using immobilized papain.

The cleaved Fabs were separated from Fc by another

application to the protein A column. In this purification the desired F abs were not
retained by the protein A column, but the undesired Fc was retained. The purities of 3E6
and G99 Fabs were assessed with SDS-PAGE and a typical gel is shown in Figure 9.

Figure 9. 10% SDS-PAGE gel of 3E6 antigen binding fragment (Fab) purification. Lanes:
1, Crude whole IgG; 2, Pure whole IgG from protein A column eluent; 3, IgG cleavage
products; 4, Pure IgG from protein A column flow-through.
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Both pure 3E6 and G99 Fabs show a double band as a result of the reduced sulfide bonds
between the heavy and light chains. Purified 3E6 shows a peptide of similar size to C2.
This peptide is likely a result of binding to a component of the crude antibodies, but it
was lost in the process of forming the binary and ternary complexes.

Mass Spectrometry

Since the 3E6 and G99 IgGs have not been sequenced, the molecular weights of the Fabs
were unknown.

In order to further characterize the F abs and to translate their

concentrations into molarity, we collected mass spectrometry data on each Fab. Mass
spectra of pure Fabs were collected using electrospray ionization on a triple quadrupole
mass spectrometer. Mass spectra are shown in Figure 10. The masses of the 3E6 and
G99 Fabs were calculated to be 46,815 and 47,622 Da, respectively.
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Figure 10. Mass spectra of 3E6 and G99 digested Fabs. The top spectrum shows mass
to charge ratios of fragmented 3E6 Fab, and the bottom spectrum shows the same for
G99 Fab. Based upon averages of several pairs of peaks in theses spectra, 3E6 and G99
Fabs were calculated to have 46,815 and 47,622 Da masses, respectively.

Formation of Complexes

Once the C2 domain and Fabs were purified and concentrated, binary and ternary
complexes were formed by 30 minutes of room temperature incubation.

Then

complexes were applied to a size exclusion chromatography (SEC) column for a final
purification. Evidence of the binding of binary and ternary complexes was provided by
SEC chromatographs. SEC elution profiles of C2, Fabs, binary and ternary complexes are
shown in Figure 11.
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Figure 11. Size exclusion chromatograms of C2, Fabs, and complexes. Elution profiles
are labeled by color in figure. SEC was performed on binary and ternary complexes in
the presence of an excess of C2 so complex elution profiles show two peaks; the peak
to the right corresponds to the elution of excess C2. The 3E6 and G99 peaks elute at
different volumes due to a contaminating peptide, but the binary complexes elute at
the same time indicating that both are bound to C2 and have no contaminants.

SEC profiles indicated the formation of binary and ternary complexes.

Peaks of

complexes could be resolved from C2, but not from pure F ab so an excess of C2 was used
in the formation of complexes and the C2 peaks are therefore present in each complex
elution profile. Eluents of pure components and complexes were assessed with SDSPAGE and the gel is shown in Figure 12.
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Figure 12. 15% SDS-PAGE gel of pure Fabs and complexes. SDS-PAGE gel of pure Fabs
and complexes with cleaved C2. Lanes: 1, G99 Fab; 2, G99:C2 binary complex; 3, 3E6
Fab; 4, 3E6:C2 binary complex; 5, 3E6:C2:G99 ternary complex. Lane 3 shows a
contaminating peptide of about 15 kDa MW in the fraction with 3E6 F ab.

The contaminating peptide of similar size to C2 is particularly visible in lane 3 of the gel
in Figure 12. The 3E6 elution peak is shifted in Figure 11 due to the contaminating
peptide. The binary complexes, however, elute at the same time indicating they are the
same size. The peptide may separate from 3E6 when C2 binds from the Fab, suggesting
that it is not present in binary or ternary complexes.

In order to show that the 15 kDa band in Lane 3 of Figure 12 was not a result of
contamination by the C2 domain, a 17% SDS-PAGE gel was run with 3E6 carefully
segregated from the lanes containing C2. This gel is shown in Figure 13.
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Figure 13. 17% SDS-PAGE gel with 3E6 Fab contamination. SDS-PAGE gel of 3E6 Fabs
and 3E6:C2 binary complex. Lanes: 1, 3E6 Fab; 2, MW standards labeled at left; 3, 3E6
Fab; 4, 3E6:C2 binary complex. Lanes 1 and 3 show a contaminating peptide of about
15 kDa MW in the fraction with 3E6 Fab. This peptide cannot be resolved from C2.

Lane 1 in Figure 13 shows the contaminating peptide more clearly than Lane 3, but the
contaminant is present in both lanes. While the 15 kDa band in Lane 3 could be the
result of contamination from Lane 4, the same cannot be said of Lane 1. The 15 kDa
band in Lane 1 is unambiguously present in the 3E6 Fab fraction. It cannot be due to the
presence of C2 since its purification was entirely segregated from C2, but its loss in the
formation of the binary and ternary complexes cannot be confirmed with SDS-PAGE
because of the overlap of the C2 band.

If this contaminating peptide was present in the crystal trials, it may have contributed to
the difficulty in growing crystals of the 3E6:C2 binary and 3E6:C2:G99 ternary
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complexes. Further work should be done to confirm whether the peptide is lost when
forming the binary and ternary complexes. This can be done by using (His)6-tagged C2
to form the complexes because the band for (His)6-tagged C2 will be higher than the
band for cleaved C2.

Binding Assay

A binding assay was developed to confirm the formation of binary complexes. (His)6tagged C2 was incubated with an equimolar amount of 1 of the F abs in the presence of
10 mM imidazole, then applied to either Ni-NTA resin or TALON resin. Both Ni-NTA and
TALON bind strongly to (His)6-tags. The resin was then washed with buffer containing
10 mM imidazole, and the washes were examined with SDS-PAGE. Next, a buffer
containing 150 mM imidazole was applied to the resin. The eluent was collected and
assessed with SDS-PAGE. Control experiments were simultaneously performed using
(His)6-tagged C2 without Fab added and Fab without C2 added. The results of the binding
assays for binary complexes are shown in Figure 14.
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Figure 14. Binding assay results for G99:C2 and 3E6:C2. 12.5% SDS-PAGE gels to assess
binding of (His)6-tagged C2 to G99 Fab (A) and 3E6 Fab (B). Lanes: 1, Wash of C2 (10 mM
imidazole); 2, Wash of Fab (10 mM imidazole); 3, Wash of binary complex (10 mM
imidazole); 4, Eluent of C2 (150 mM imidazole); 5, Eluent of Fab (150 mM imidazole); 6,
Eluent of binary complex (150 mM imidazole). Note that EZ-Run and Spectra protein
ladders were used in A and B, respectively.
(His)6-tagged C2 was not detected in the washes, but it was detected in the eluents
indicating that the (His)6-tagged C2 bound to the resin. In both assays, the Fabs were
detected in the washes, but not in the eluents indicating that they did not bind to the
resin. In each binding assay, weak bands indicating Fab were detected in the wash lanes
(Figure 14A and 14B, Lane 3). Stronger Fab bands were detected in the eluent lanes,
though, so the Fabs appeared to bind (His)6-tagged C2.

SAXS Data

SAXS data were collected by beamline scientists at the Advanced Light Source at
Berkeley. Scattering curves were collected using the BL12.3.1 beamline on the 3
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concentrations of each 6 samples: C2, 3E6 Fab, G99 Fab, 3E6:C2, G99:C2, 3E6:C2:G99 The
scattering curves for each concentration were normalized for concentration, then
combined, and the scattering due to an identical buffer was subtracted from the
combined curve. The data were analyzed by the procedure in Appendix 1. The data
processing procedure is outlined in Figure 15.

Figure 15. Flowchart of SAXS data processing. Scattering curves collected by beamline
scientists were input into PRIMUS. PRIMUS yielded parameters, plots, and merged
curves. The merged curves were input into GNOM which yielded further parameters
and P(r) distribution curves. P(r) curves were input into DAMMIN to elicit an ab inito
shape. The merged curves from PRIMUS were also input into CRYSOL with atomic
coordinates of known structures, and a structure file was output. The PRIMUS merged
curves, structure file output from CRYSOL, and coordinate files of known structures
were input into SASREF to elicit a coordinate file with artificially high resolution.
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A Guinier plot is a plot of natural log of I(q) versus q 2 (see page 21 and Appendix 1), and
a linear Guinier plot is generated when samples are monodisperse [97]. A curved
Guinier plot indicates aggregation [97]. Guinier plots were generated for each of the 6
samples using PRIMUS software [91], and they are shown in Figure 16. All six Guinier
plots were linear with an insignificant upward curvature near the y axis. This linearity
indicated that aggregation was not present in any of the samples [97]. The Guinier plots
also produced I(0) and RG values discussed below.
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Figure 16. Guinier plots of SAXS samples. Guinier plots were generated by PRIMUS
software. Complexes are labeled in figure. Y axes are ln[I{q)] and x axes are q 2 as
described in background section. Residuals are shown toward bottom of graphs.

Pair distribution functions P(r) for each of the 6 samples were generated by GNOM
software [92] and are shown in Figure 16. The shape of the pair distribution functions
gives some information about the globular nature of the sample. A single, bell-shaped
curve indicates a globular protein [97]. Multiple peaks indicate a multi-domain protein
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[97]. Each of the six pair distribution functions shows a single major peak. All of the
samples are known to have multiple domains, but this is most clearly shown in the pair
distribution function for the ternary complex with additional peaks at 90Å and 135Å.
GNOM software also produces values called real space I(0) and real space RG, and these
values are shown in Table 2.

Figure 17. Pair distribution functions of SAXS samples. Pair distribution functions
were generated by GNOM software. Complexes are labeled in figure.
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Table 2. Table of SAXS parameters. RG and I(0) are based on Guinier plot output from
PRIMUS software. Real space RG and I(0) and Dmax are based on output from GNOM
software. Molecular weight (MW) for 3E6 and G99 F abs are from mass spectrometry
data. MW for C2 is known, and binary and ternary complex MW data are sums of
components’ MWs. Concentrations listed are stock concentrations, and SAXS data
was collected for the stock solution and 2:1 and 1:2 dilutions of the stock.

The trends of the values for RG and Dmax in Table 2 are generally in agreement with the
increasing sizes of the complexes. Since 3E6 and G99 Fabs are expected to be very
similar in size and shape, a similar RG is expected. The 3E6 and G99 Fabs have RG values
of 27.7 Å and 27.0 Å, respectively. Although the MW of 3E6 is smaller than the G99
MW, the RG for 3E6 is larger than that of G99. This discrepancy may be due to the
contaminating peptide attached to 3E6 as described above. However, the RG value is a
measure of mass distribution around the center of gravity and, as such, it can vary
within similar sizes. The I(0) trends are in agreement with the MW trends, and the I(0)
increases with increasing MW. The real space values for I(0) and RG are in agreement
with the I(0) and RG values from the Guinier plot. The biggest difference between real
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space and Guinier values is between the 3E6 real space I(0) and Guinier I(0) (329.9 Å and
290.05 Å, respectively). Since the real space I(0) uses all scattering data and Guinier I(0)
uses truncated data, the higher real space I(0) may have resulted from degradation of
the Fab during longer exposures.

DAMMIN software [93] was used to produce ab initio shapes. The software uses a
simulated annealing procedure to arrange a finite number of spheres into a shape that
would theoretically generate the scattering curves if it were dispersed in solution [86].
This model is built according to constraints provided by upstream SAXS software and the
parameter Dmax as input by the user. The molecular envelope was generated using the
same raw data 10 times by the user to ensure reproducibility of the shape. The shapes
can then be inspected for similarity or averaged. DAMMIN software generated low
resolution envelopes for the binary and ternary structures shown in Figure 18.
Reproducibility of these models was verified by performing 10 iterations of each shape.
The ternary structure appears elongated with C2 at its center and Fabs on opposing sides
of C2.
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Figure 18. SAXS molecular envelopes of ternary and binary structures. Ternary (A),
binary 3E6:C2 (B), and binary G99:C2 (C) molecular envelopes are each shown twice.
Bottom image is rotated 90° from top image in A, B, and C. Binary complexes (B and
C) appear more dense because each molecular envelope is created with the same
number of spheres.

The G99 binary shape in Figure 17 appears shorter than the 3E6 binary shape, but the
G99:C2 has a larger Dmax than the 3E6:C2. This discrepancy may be due to some
flexibility in the binary compounds. Although the shapes output by DAMMIN and shown
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in Figure 18 are based upon averaged scattering data, they are nonetheless static and
low resolution structures. The binary shapes also indicate by the more globular nature
of the 3E6:C2 model that the C2 domain may have more buried surface area in the 3E6
Fab than in the G99 Fab. The ternary shape in Figure 18 is unambiguously longer than
both the binary shapes. Figure 18 below indicates that the C2 is the shape in the center
of the ternary DAMMIN structure in Figure 18, and the Fabs are elongated in opposite
directions.

The merged scattering curves output by PRIMUS were combined with crystal structures
from the Protein Data Bank using CRYSOL software [94]. The CRYSOL output was a
spatial file used to create the structures shown in Figure 19 using SASREF software [95].
SASREF software, like DAMMIN, uses simulated annealing. The crystal structure of the
C2 domain was used for generating SASREF shapes (PDB accession number 2R7E) [42].
The Fab of an anti-HIV IgG 13H11 was used for modeling for both 3E6 and G99 F abs (PDB
accession number 3MNW). The anti-HIV antibody was chosen arbitrarily since 3E6, G99,
and 13H11 are all monoclonal mouse anti-human IgGs but the amino acid sequences of
3E6 and G99 are unknown. The sequences for the three Fabs are likely very different,
but any canonical heavy chain and light chain conformation of the same group and
species is expected to adopt the conserved global IgG conformation. Although structure
is typically highly homologous for immunoglobulins of the same class, the
complementarity determining region (CDR) of an antibody is distinctive. The CDR of
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13H11 is certainly different than the CDRs of 3E6 or G99, but there are penalties in
SASREF software for unfavorable side-chain contacts. Therefore inputting the CDR of
the model Fab may generate different contacts with C2 than inputting the true CDR of
3E6 or G99 Fab. For that reason the specific contacts modeled in Figure 19 are not
certain.

Figure 19. SAXS ternary structure generated with molecular replacements. G99 F ab is
green, C2 is red, and 3E6 Fab is violet. Bottom image is rotated 90° from top image.
Molecular replacement is responsible for artificially high resolution.
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Every generation of SASREF shapes yielded a structure with the C2 domain at the center.
Constraints were used to ensure correct orientation of the F ab when generating the
SASREF structures in Figure 18. Without constraints, SASREF generated structures with
the CDR loop oriented away from the C2 domain instead of in contact with it. This type
of incorrect structure was probably due to the internal symmetry of a Fab which looks
similar in both orientations. When the antibody is acting in vivo, the CDR loop of the Fab
is in contact with the antigen and the other side of the F ab is in contact with the other 2
fragments of the antibody. Therefore, the CDR loop in the model must be the side of
the Fab in contact with the antigen. To address this issue, the 3E6:C2 binary shape was
generated with a contact condition in place that penalized against a distance greater
than 35 Å between C2 residue M2321 and a residue central to the CDR loop of 3E6. This
condition allowed for any orientation of the C2 domain, but the contact between C2 and
the Fab had to be in the CDR of the Fab. The ternary structure was then generated by
joining the G99 Fab to the 3E6:C2 binary complex. A contact condition penalized a
distance greater than 25 Å between the C2 residue K2227 and 2 residues central to the
CDR of the G99 Fab. The K2227 residue of C2 was selected because it is known to be in
or near the G99 epitope on C2 as discussed in the Background Section. Once these
minimal constraints were in place, reproducible ternary models were generated.

Figure 19 was derived from PDB coordinate files with atomic resolution, but the high
resolution is due to the crystal structure molecular replacements for the components.
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Due to the globular nature of C2 and the close packing of its domains, the orientation of
C2 in Figure 19 requires verification. X-ray crystallography data is needed for such a
confirmation, and crystals of the binary and ternary complexes have so far proven
elusive. The orientation of C2 was reproduced in some, but not all, generations of the
structure by SASREF.

The ternary structure in Figure 19 shows 3E6 in contact with the hydrophobic spikes of
the C2 domain. This shape corroborates the evidence that the hydrophobic spikes of
the C2 domain are blocked from binding to vWF and to phospholipids by the 3E6
antibody. The classical antibody 3E6 binds competitively with phospholipid and vWF.
Since the phospholipid and vWF binding region has several solvent-exposed
hydrophobic loops, an antibody binding to this region of C2 is likely to bury those loops
in its CDR region. The nonclassical antibody inhibits activation of FVIII by thrombin or
FXa. Since thrombin and FXa activate by cleavage of specific residues, less contact
needs to be made between the Fab and C2 to sterically block access to several residues.

The FVIII heavy and light chains are more stable when in contact with vWF so it is
possible that the classical antibody blocking the access to vWF destabilizes the
association of the heavy and light chains of FVIII. While the nonclassical antibody
against FVIII allows binding to vWF, it blocks activation by thrombin. If FVIII is not
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cleaved, it is not able to take part in the intrinsic tenase complex. As a result, the FIX is
not recruited as often to the phospholipid surface, and cleavage of FX is greatly reduced.
The elongated ternary structures in Figures 18 and 19 are also in agreement with the
junction requirements for 3 large molecules.

Since 3E6 and G99 IgGs bind

simultaneously to the C2 domain of FVIII, their epitopes must be far enough apart that
the additional IgG fragments do not sterically clash. In vivo the C2 epitopes are also
constricted by the adjacent C1 and A1 domains. Although the C2 domain is the most
solvent-exposed domain of free FVIII, access to its epitopes is nonetheless limited by
neighboring domains. The elongated ternary structure of C2 and the 2 Fabs is therefore
plausible, and it is likely that the DAMMIN and SASREF shapes are an accurate
representation of classical and nonclassical antibody action against C2.

The entire B-domain deleted FVIII molecule was modeled into the ternary structure to
check for steric clashing. No clashing was observed between the F abs and the domains
of FVIII, and this model is shown in Figure 20.
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Figure 20. SAXS ternary structure with entire FVIII. The entire B-domain-deleted FVIII
is modeled in the ternary structure. The red C2 domain and the violet 3E6 and green
G99 Fabs are labeled in figure. No steric clashing is observed between the Fabs and any
of the FVIII domains: A1 (blue), A2 (green), A3 (yellow), and C1 (orange).

Although the orange C1 domain in Figure 20 is near the Fabs, no steric clashing is
observed indicating that the ternary structure is possible.

The DAMMIN and SASREF structures in Figures 18 and 19 were compared with each
other using SUPCOMB software [96] which overlays pdb files by searching for greatest
possible overlapping electron density. The overlaid structures are shown in Figure 21.
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Figure 21. Overlaid SAXS ternary structures. The DAMMIN and SASREF shapes are
overlaid to demonstrate similarity. SASREF model is shown as colored mesh, and G99
Fab is green, C2 is red, and 3E6 Fab is violet. DAMMIN model is shown as black spheres.

The agreement between the DAMMIN and SASREF results is additional evidence of the
plausibility of the elongated ternary structure. Although the same merged scattering
curves and the same software suite are the bases for both ternary structure results, the
pathways to reach the structures are distinct. The generation of similar structures by
two different simulated annealing procedures indicates the reproducibility of the
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structure. The reproducibility is also supported by the repeated iterations of each shape
determining procedure. Additionally, the raw data was collected at 3 exposures for
each of 3 concentrations on complexes and components, and the input into both
DAMMIN and SASREF were merged files of 9 scattering plots for each complex and
component. The ternary and binary structures are thus useful to verify future X-ray
crystallography data.

Conclusions

The C2 domain is critical for FVIII function. When vWF, phospholipid membrane, and
thrombin access to C2 is blocked by classical or nonclassical antibodies, FVIII activity is
compromised. When both types of antibody are present FVIII is unable to fulfill its role
in the blood coagulation cascade. Understanding the role of inhibitory antibodies is
critical for the treatment of hemophilia A.

The specific aims of this study were 1) to prepare pure C2 domain, 3E6 F ab, and G99 Fab;
2) to purify 3E6:C2 and G99:C2 binary complexes and 3E6:C2:G99 ternary complex; 3) to
characterize complexes with SAXS; and 4) to perform crystal trials to prepare for X-ray
crystallography. The C2 domain and the G99 Fab were prepared to high purity, and the
3E6 Fab was prepared to sufficient purity for SAXS collection despite an errant
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contaminating peptide so the first aim was accomplished. Binary and ternary complexes
were successfully formed and purified so the second aim was achieved. The third aim
was completed because SAXS data were collected at a synchrotron and processed with
two pathways of software to generate a reproducible and comparable elongated
ternary structure. Extensive crystal trials are currently being monitored for promising
crystal growth conditions so the fourth aim was accomplished.

The elongated ternary structure and accompanying binary structures generated by SAXS
data are reproducible and based upon multiple scattering curves for each shape. The
ternary model of 3E6:C2:G99 allows space for the additional FVIII domains and IgG
fragments present in in vivo complex. The shapes generated by SAXS will therefore be a
useful complement to X-ray crystallography data on the complexes.
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Appendix 1: Instructions for Processing SAXS Data
These instructions are intended for the preparation of samples for small angle X-ray
scattering (SAXS) and the processing of SAXS data. PRIMUS [91], GNOM [92], DAMMIN
[93], CRYSOL [94], SASREF [95], and SUPCOMB [96] are the software programs
discussed, and they were all downloaded as part of a software suite called ATSAS
Version 2.3 from the excellent European Molecular Biology Laboratory (EMBL) website
[98, 99]. The software was written by EMBL Hamburg’s Dmitri Svergun and colleagues
and additional software programs are available as part of the ATSAS suite with
redundant functions and online tutorials.

These instructions include examples from the processing of data in the current study
which employed the Structurally Integrated Biology for Life Sciences (SIBYLS) Beamline
[100] at the synchrotron at the Lawrence Berkeley National Lab (LBNL) in Berkeley,
California in May and June of 2011. The instructions do not include comprehensive
SAXS theory or exhaustive use of software programs. These instructions are partially
adapted from the very useful Biologically Integrated Structures In Solution (BIOISIS)
website [101] written by Dr. Robert P. Rambo of LBNL. Although the BIOISIS and EMBL
websites are extensive resources which should be explored by any SAXS user, neither
site contains all of the instructions presented here.
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Parameter
q, s
RG

Dmax

I(0)

Definition
Momentum transfer
q = 4πsin(θ)/λ
Radius of gyration - mass
distribution of
macromolecule around
center of gravity
Longest distance between
two electrons in
macromolecule
Extrapolated intensity of
scattered X-ray at zero
momentum transfer
Same as RG above

Output from Software

Notes

PRIMUS (From Guinier
Plot)

2θ is angle of
scattering
Uses some data
points

GNOM, Perl script

PRIMUS (From Guinier
Plot)

Real Space
RG
Real Space
Same as I(0) above
I(0)
Table A-1. Table of SAXS parameters.

Plot
Guinier Plot

Kratky Plot

GNOM (From P(r)
distribution)
GNOM (From P(r)
distribution)

Definition
Software
Y-axis
Natural log of
PRIMUS ln(I)
intensity of
momentum transfer
versus squared
scattered angle

Product of intensity
of scattered angle
and squared
scattered angle
versus scattered
angle
P(r)
Distribution of
Distribution distances between
pairs of electrons

PRIMUS

I(q)•q2,

X-axis
q , s2
2

q, s

I(s)•s2

GNOM

P(r)

Table A-2. Table of plots derived from SAXS data.
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r, length
between
pairs of
electrons

Uses all data points

Notes
Y-intercept is
extrapolated
intensity at zero
angle; slope is
2
RG /3; indicates if
aggregation is
present
Shows whether
macromolecule is
folded or unfolded

Shows whether
macromolecule is
globular or
multidomain

Sample Preparation
Some of the scattering of X-rays in SAXS is due to the buffer. For that reason, a buffer
identical to the buffer containing the macromolecule of interest must be provided with
samples sent to the beamline. Buffer exchange using either a concentrator or dialysis is
an acceptable method to ensure a buffer is identical. The scattering due to the buffer
will be subtracted from the sample scattering before analysis. This may be done by the
beamline scientists at the time the SAXS profiles are taken. Specific instructions for
preparing, labeling, and shipping samples are stringent and subject to change. The
instructions are available on the website for the SIBYLS Beamline BL12.3.1.

Beamline scientists will collect scattering data at three different time intervals. After
collecting raw data, beamline scientists will send a group of dat files for processing.
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Data Processing

Use PRIMUS to make Kratky plots and merge raw dat files

PRIMUS software is used to make Kratky plots and to merge the data from different
exposures. A Kratky plot of a single exposure of a macromolecule indicates whether the
protein is unfolded. Merged data is a combination of multiple curves with different
exposure times and/or sample concentrations.

Open PRIMUS to see the empty window in Figure A-1.
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Tools

Figure A-1. Screenshot of PRIMUS software initiation.

Click on Tools in the upper left hand corner. Click Select to open a window containing
your data (Figure A-2). Then select a data file with tab delimited data (scattering angle,
intensity or scattering angle, intensity, error). Once the file is selected, click Sasplot
(Figure A-2). A window with a plot will open.
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Select data

Create Kratky plot

Figure A-2. Screenshot of PRIMUS software for creating Kratky plot.

The plot that is created is not truly a Kratky plot. A Kratky plot has as its y-axis the
product of the intensity of the scattered X-ray, I(s) or I(q), and the momentum transfer
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squared, s2 or q2. The x-axis is the scattered angle. Display a Kratky plot by selecting
view in the plot window shown in Figure A-3 and choosing “Y*X^2 : X” from the dropdown menu. A resultant Kratky plot is shown in Figure A-4.

Display Kratky plot
from View dropdown menu

Figure A-3. Screenshot of Sasplot for displaying Kratky plot.

Figure A-4. Screenshot of Kratky plot.
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Further manipulations of plots can be done in GNUPLOT or R software. Compare Kratky
plots to guidelines in Figure A-5.

Figure A-5. Guidelines for interpreting Kratky plot [97]. The characteristic Kratky plot
of an unfolded protein shows a plateau. The characteristic Kratky plot of a folded
protein shows a bell-shaped curve. A partially unfolded protein’s Kratky plot is an
intermediate of the described curves.

In Figure A-6 3 dat files of ternary complex are chosen. They are the 3 different
exposure times for 1/3 concentration of ternary complex.
data.
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Then click on Plot to plot

Defines number of data points
from BEGinning to END

Plot data

Figure A-6. Screenshot of PRIMUS software for merging data: first example.

The curves in Figure A-6 overlap because the data was normalized and integrated by
beamline scientists. The y-axis shows the log of intensity and the x-axis shows scattering
angle s (also called q). Typically, the shorter exposure gives more reliable data at low
scattering angle, but gets noisier at higher scattering angle. The longer exposure is
more reliable at higher scattering angle, but tends to become over-exposed at low
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scattering angle. This is not evident in our data, though, and we selected the least noisy
part of the curves for each exposure by adjusting the nBeg and nEnd.

In Figure A-7 there are 9 files selected. They are the 3 exposures of each 1/3, 2/3, and
full concentration of the protein domain C2. Their nBeg and nEnd is adjusted to
minimize noise in curves. The multiplier value is set according to concentration. The
1/3 concentration files are multiplied by 3, the 2/3 concentration files are multiplied by
1.5, and the full concentration files are multiplied by 1.

Merge
Figure A-7. Screenshot of PRIMUS software for merging data: second example.
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Clear

Once the nBeg, nEnd, and Multiplier values are set by the user, click Merge (Figure A-7).
The Multiplier values will be adjusted by the software, and will no longer be integers. A
merged file will be created in the same folder as the dat files. Rename the file once it
has been created so it is clear which sample’s dat files have been merged. Also, keep
track of the nBeg, nEnd, and Multiplier values set. Once the merged dat file has been
made, the other files can be removed from the window by hitting Clear (Figure A-7) and
the merged dat file can be selected and plotted as shown in Figure A-8.

Guinier

Figure A-8. Screenshot of merged data in PRIMUS software.
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Use PRIMUS to find RG and I(0)

With the merged file plotted, click Guinier (Figure A-8). An unsuitable Guinier plot will
be generated and it can be adjusted to get a reliable RG and I(0). The product of q*RG
(shown as sRG upper range) should be less than 1.3 (Figure A-9).

This range is

accomplished by removing data points at higher scattering angle by setting a low nEND.
50 data points are enough, but many more may fit. When selecting data points, pay
attention to residuals to avoid data bias. Residuals should appear to be random if data
is not biased. Click Guinier again to generate a plot showing RG and I(0) as in Figure A-9.
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< 1.3

RG and I(0)
Residuals

Figure A-9. Screenshot of Guinier plot. The upper limit of the product of the
scattering angle and RG should be less than 1.3.

The Guinier plot is the linear plot of natural log of intensity, ln(I), vs. squared
momentum transfer, q2 or s2. The intercept is the extrapolated intensity of scattered Xrays at zero angle, and the slope is the negative square of RG divided by 3.

Use GNOM or Perl scripts to find the Dmax

The Dmax is the maximum dimension of the molecule. It is solved by iteratively entering
values for Dmax into GNOM software and comparing the GNOM output to find the most
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suitable value. Dr. Spiegel did this on a Mac with Perl scripts to make an output of
graphs. Figure A-10 shows the output for the ternary complex:

Figure A-10. GNOM output for determination of Dmax. The Dmax was determined to be
170 Å based upon the discrepancy (top left), stability (middle left), and systematic
deviations (middle right).

In the example shown in Figure A-10 170 Å was chosen as the Dmax. On a PC, you can
run MatLab to the same end.

74

Use GNOM to find P(r), Real Space RG, and Real Space I(0)

GNOM software is used to find P(r) and real space RG and I(0). P(r) is the distribution
function of distances between pairs of electrons. P(r) changes as macromolecules
change form so it is most useful for verifying conformational change. In the current
study, we did not look for or see conformational change and used the P(r) function only
to find real space RG and I(0). The shape of the P(r) curve can also indicate whether the
macromolecule is globular.

Figure A-11. Guidelines for interpreting P(r) distribution [97]. The characteristic P(r)
distribution of an unfolded protein (red) has a longer tail at high distance between
electrons (r). A globular protein (blue) displays a bell-shaped curve. A multidomain
protein (black) have multiple peaks.
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RG is calculated from the P(r) function by GNOM software.

Once the original dat files have been merged and you have a Dmax, open GNOM
software. You will be prompted to select the first file name. Choose the merged dat file
that was output from PRIMUS. You will be prompted to select the output file name.
Type SampleName_gnom.out, then press enter several times to accept the preset
conditions

A graph will appear as in Figure A-12.
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Figure A-12. Screenshot of GNOM software.

Press enter several more times until prompted to enter an Rmax for evaluating P(r).
Enter here your Dmax, the maximum dimension of the complex as determined above.
Press enter a few times to accept preset conditions.

Press enter twice to see a graph as in Figure A-13 with the real space R(g) and I(0) in it.
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Real space RG and I(0)

Dmax

Figure A-13. Screenshot of GNOM software displaying real space RG and I(0) and Dmax.

Press enter a few more times until program closes. Now there is a gnom.out file that
can be used for ab initio modeling in DAMMIN software.

The gnom.out file can be opened in Microsoft Excel. The Dmax is shown as the upper end
of the real space range as in Figure A-14.
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Dmax

Figure A-14. Screenshot of Microsoft Excel spreadsheet displaying Dmax.

The real space R(g) and I(0) are listed at the end of the file as shown in Figure A-15.

Real space
RG and I(0)
Figure A-15. Screenshot of Microsoft Excel spreadsheet displaying real space RG and
I(0).

By delimiting the data, you can make a graph of P(r) distribution, which is P(r) vs. r.
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Use DAMMIN to make pdb ab initio structures

Ab initio, “from the beginning”, structures are the assignments of low-resolution
electron density spheres based on the scattering of small-angle X-rays: they are the
heart of SAXS data.

When DAMMIN software is opened, “Log file name” prompts the user to name the
output file. For example, the user could type NameGiven. Next, “PLEASE SELECT THE
INPUT FILE NAME” prompts you to select gnom.out file. Press enter several times to
accept preset conditions.
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Figure A-16. Screenshot of DAMMIN software.
DAMMIN will begin simulated annealing and will take 10 minutes to a day and a half
depending on computer and size of molecule.
Five output files are produced:
For “NameGiven”
1. NameGiven-0.pdb
2. NameGiven-1.pdb
3. NameGiven.fir
4. NameGiven.fit
5. NameGiven.log
The -0.pdb file is a sphere
The -1.pdb file is the one to use.
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Perform 10 independent runs in DAMMIN. That is, run DAMMIN 10 times with the
same input file, and number your outputs. Compare the -1.pdb files using Pymol to see
that they all look the same.

Next, DAMAVER software can be utilized to average the 10 independent runs. In the
current study, DAMAVER was not accessed, and a typical DAMMIN output file was used
instead.

Use CRYSOL to compare known structure pdb files to merged SAXS
scattering data
First Download a pdb file of the known crystal structure of the molecule and put it into
the same folder as the dat files into which CRYSOL will output its alm file for use in
SASREF.

Note that since the output of CRYSOL is the name of the pdb file, using a pdb file to
compare a molecule automatically overwrites the files previously compared to that pdb
file. So when using a pdb file of a generic-looking Fab, save 2 copies of it for comparison
with 2 different Fab data sets.

Choose a pdb file to compare to your scattering curve. For comparison with a scattering
curve of a Fab fragment of an IgG, a pdb file of another IgG is chosen from the Protein
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Data Bank. Push enter to accept preset conditions. When prompted, open the merged
data file. Press enter to accept preset conditions.

Output is 3 files:
1. Data fit saved to file NameOfPDBFile00.fit
2. Intensities saved to file NameOfPDBFile00.int
3. Net amplitudes saved to file NameOfPDBFile00.alm

Use SASREF to make pdb ab initio structures

SASREF requires alm files from CRYSOL, pdb files from the Protein Data Bank, and dat
files of merged data from PRIMUS. Use the following guidelines for initiating a run:

Enter log file name: TypeOfSample
Input total number of subunits: For a binary complex, enter 2.
Input total number of scattering curves: 3 is entered here because there is a
scattering curve for each monomer and for the heterodimer.
Input first and last subunits in 1st construct: 1,1

Figure A-17 shows an example log with inputs in green. Separate subunits with commas
when inputting first and last subunits.
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=== SASREF06 started at
29-Jul-2011 15:24:44
Computation mode ....................................... : User
Project identificator .................................. : C23E6t
Project decsription
Random sequence initialized from ....................... : 152507
Total number of subunits ............................... : 2
Point symmetry of the particle ......................... : P1
Number of equivalent positions ......................... : 1
Total number of scattering curves ...................... : 3
1-st construct, the first and the last subunits: 1 and 1
File name, 1-st experimental data ...................... : Merge_C2_RW.dat
Number of experimental points found .................... : 526
Experimental radius of gyration ........................ : 16.64
Number of points in the Guinier Plot ................... : 94
2-nd construct, the first and the last subunits: 2 and 2
File name, 2-nd experimental data ...................... : Merge_3E6_RW.dat
Number of experimental points found .................... : 299
Experimental radius of gyration ........................ : 36.29
Number of points in the Guinier Plot ................... : 22
3-rd construct, the first and the last subunits: 1 and 2
File name, 3-rd experimental data ...................... : Merge_3E6_C2_RW.dat
Number of experimental points found .................... : 526
Experimental radius of gyration ........................ : 31.46
Number of points in the Guinier Plot ................... : 41
Amplitudes, 1-st subunit ............................... : 3NL4GenericFab00.alm
Number of points in partial ampliudes .................. : 51
Maximum order of harmonics ............................. : 15
Evaluated from the file ................................ : 3NL4GenericFab.pdb
Current subunit: 3214 atoms read, center at -26.07 22.64 -18.13
Spatial step in angstroems ............................. : 5.000
Angular step in degrees ................................ : 20.00
Amplitudes, 2-nd subunit ............................... : 1D7P00.alm
Number of points in partial ampliudes .................. : 51
Maximum order of harmonics ............................. : 15
Evaluated from the file ................................ : 1D7P.pdb
Error reading pdb file 1D7P.pdb ....................... : 1D7P00.alm
Number of points in partial ampliudes .................. : 51
Maximum order of harmonics ............................. : 15
Evaluated from the file ................................ : 1D7P.pdb
Select Contacts Conditions file: Cancel
==============================================================

Figure A-17. Sample SASREF processing log. Information input by user is shown in
green. Misspelled prompts are common in ATSAS software.
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SASREF begins an iterative process. A typical screenshot is shown in Figure A-18.

Figure A-18. Screenshot of SASREF processing ab initio shapes. The top left is one of
two monomers, the bottom left is the other monomer, and the heterodimer is shown
to the right.

The output of SASREF is a pdb file which can be opened in a program such as Pymol.
SASREF may produce nonsensical ab initio structures. For example, one monomer may
be oriented in a way that is known to be impossible. For orienting components of
complexes in SASREF, a contact conditions file can be utilized.
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Use SASREF online [98] to create contact conditions file

The contact conditions file allows you to say there must be a minimum distance
between an amino acid in one subunit and an amino acid in another. There are
indecipherable instructions for making a contact conditions file with Notepad in the
SASREF manual. An easier option is to access SASREF online.

You will need to create an account or enter your username (your email address) and a
password. For the current study, the following username and password were used:
Rachel Werther’s username: werther2@students.wwu.edu
Rachel Werther’s password: sRoTxKeE
If you aren’t prompted to enter a username and password, the results may be emailed
to a preset address and lost.

Next choose the appropriate responses to the prompts. For example:

Total number of curves: 3
Total number of subunits: 2
Overall symmetry: P1
Click Submit. On the next screen provide your SAXS curve(s) and the subunits and check
Provide contact conditions. Click Submit. On the next screen enter the distance in Å,
choose the first subunit and the last C-α, choose the second subunit and the first C-α.
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When you submit, SASREF online will run a simulated annealing procedure, and you will
get a zip file by email at the address you used as a username.

Use SUPCOMB to generate superimposed structures

SUPCOMB [96] requires 2 pdb files and quickly generates a pdb file of 1 of the structures
in the appropriate orientation to superimpose onto the other. Save pdb files in the
same folder containing the SUPCOMB program. Keep the file open on the desktop and
click and drag each file into SUPCOMB window when prompted. Accept all other
presets.
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